Investors Urged to Lead Class Action Against uniQure N.V. for Securities Fraud
On April 7, 2026, the Rosen Law Firm, a prominent global law firm focused on investor rights, issued a reminder for investors who purchased shares of uniQure N.V. (NASDAQ: QURE) during the Class Period from September 24, 2025, to October 31, 2025. This alert coincides with the impending April 13, 2026 deadline for investors to act as lead plaintiffs in a class action lawsuit that has been filed against uniQure for alleged securities fraud.
The allegations against uniQure revolve around misleading statements made regarding the approval status of their pivotal study related to a drug candidate for Huntington's disease. The lawsuit asserts that the defendants did not fully disclose the lack of approval from the U.S. Food and Drug Administration (FDA) concerning the study's design. Furthermore, it claims that the success of their pivotal study results was overstated, implying that uniQure would have to postpone its Biologics License Application (BLA) submission for further studies, which undermined the veracity of the company's statements about its business and prospects.
This misrepresentation likely caused financial damages to the investors who purchased shares during the Class Period once the reality emerged. Now, affected investors have the opportunity to recover losses, engaging in the legal process free of any upfront costs through a contingency fee arrangement.
Investors wishing to join the class action are encouraged to visit the Rosen Law Firm's website at rosenlegal.com or can directly contact attorney Phillip Kim via phone at 866-767-3653 or email at [email protected]..
For those interested in being a lead plaintiff, it is essential to file a motion with the court by April 13, 2026. The role of a lead plaintiff is crucial as they represent the interests of all class members and direct the litigation process.
Rosen Law Firm emphasizes the need for investors to select a law firm with proven experience and success in handling securities class actions. Many firms that provide initial notices may not have the necessary credentials or resources to effectively litigate these cases. Rosen Law Firm boasts a strong track record, having managed the largest securities class action settlement against a Chinese company and topping the charts for securities class action settlements since 2013, recovering significant amounts for investors over the years.
As the April 13 deadline approaches, investors who suffered due to the alleged fraudulent actions of uniQure are encouraged to consider their options carefully. The filing of this class action lawsuit provides a potential avenue for recovering losses incurred during the Class Period without incurring direct legal fees. For the latest updates, investors can follow the firm on their social media channels including LinkedIn, Twitter, and Facebook. For more inquiries, the Rosen Law Firm can be reached directly through their offices in New York.
This is a crucial moment for investors in uniQure N.V. to understand their rights and take necessary actions to potentially recover financial losses suffered due to misleading practices within the company’s disclosures.
Background of the Case
The allegations against uniQure revolve around misleading statements made regarding the approval status of their pivotal study related to a drug candidate for Huntington's disease. The lawsuit asserts that the defendants did not fully disclose the lack of approval from the U.S. Food and Drug Administration (FDA) concerning the study's design. Furthermore, it claims that the success of their pivotal study results was overstated, implying that uniQure would have to postpone its Biologics License Application (BLA) submission for further studies, which undermined the veracity of the company's statements about its business and prospects.
This misrepresentation likely caused financial damages to the investors who purchased shares during the Class Period once the reality emerged. Now, affected investors have the opportunity to recover losses, engaging in the legal process free of any upfront costs through a contingency fee arrangement.
How to Participate
Investors wishing to join the class action are encouraged to visit the Rosen Law Firm's website at rosenlegal.com or can directly contact attorney Phillip Kim via phone at 866-767-3653 or email at [email protected]..
For those interested in being a lead plaintiff, it is essential to file a motion with the court by April 13, 2026. The role of a lead plaintiff is crucial as they represent the interests of all class members and direct the litigation process.
The Importance of Choosing Qualified Counsel
Rosen Law Firm emphasizes the need for investors to select a law firm with proven experience and success in handling securities class actions. Many firms that provide initial notices may not have the necessary credentials or resources to effectively litigate these cases. Rosen Law Firm boasts a strong track record, having managed the largest securities class action settlement against a Chinese company and topping the charts for securities class action settlements since 2013, recovering significant amounts for investors over the years.
Conclusion
As the April 13 deadline approaches, investors who suffered due to the alleged fraudulent actions of uniQure are encouraged to consider their options carefully. The filing of this class action lawsuit provides a potential avenue for recovering losses incurred during the Class Period without incurring direct legal fees. For the latest updates, investors can follow the firm on their social media channels including LinkedIn, Twitter, and Facebook. For more inquiries, the Rosen Law Firm can be reached directly through their offices in New York.
This is a crucial moment for investors in uniQure N.V. to understand their rights and take necessary actions to potentially recover financial losses suffered due to misleading practices within the company’s disclosures.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.